Here SRPX2, a significant portion of ECM [14], was introduced, and it has been acknowledged to reinforce chemotolerance of tumors, such as temozolomide-resistance of glioblastoma and cisplatin-resistance of esophageal cancer [35,36]. Here, SRPX2 is linked to glioblastoma.